Charles River Laboratories International, Inc.
CRLHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Charles River Laboratories International, Inc. focuses on Diagnostics & Research services and products. Charles River Laboratories International, Inc. The $13.90B market capitalization puts CRL squarely in large-cap range for its industry. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$13.90B
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
22.74
EPS (TTM)
$-4.82
EPS (Fwd)
$12.69
ROE
-7.5%
ROA
4.1%
Cash
$192.0M
Total Debt
$3.03B
Free CF
$468.9M
52W Change
83.3%
Annual Financials
Cash vs Debt
Where CRL stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, CRL finished 45.24% above its 150-day moving average ($198.46) and 45.77% above its 200-day moving average ($197.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRL overbought or oversold?
At the September 1, 2026 close, CRL's RSI(14) was 55.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $192.0M in cash, though total debt stands at $3.03B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $468.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -7.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.54B to $4.02B.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Charles River Laboratories International, Inc. and its sector.